Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leronlimab + Regorafenib in CCR5+ MSS mCRC
NCT05730673Phase 2Withdrawn
- Sponsor
- CytoDyn Inc.
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
01
Overview
A Phase 2 trial of leronlimab in metastatic colorectal cancer (mCRC), sponsored by CytoDyn Inc.. Planned start Sep 2022; status: withdrawn.
02
Drugs
leronlimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05730673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05730673.